Skip to content
Companies

Pangia Biotech

Urine-based cancer tests, starting with prostate

Raised to date

$1.6M

of $1.6M offered across 1 Form D filing

Investors
18
Last filed
May 11, 2026

About

PanGIA Biotech is a Delray Beach, Florida biotechnology company developing non-invasive liquid biopsy tests for early cancer detection. Its PanGIA Analysis System profiles biomolecular signatures in urine and cerebrospinal fluid and applies machine learning pattern recognition to detect cancer as early as Stage 1. Its lead product, the PanGIA Prostate assay, is an AI-integrated urine-based liquid biopsy for prostate cancer; a peer-reviewed study in Diagnostics reported 97.8% sensitivity, and the company announced a partnership to commercially launch the assay in India. Assays for roughly ten additional cancers, including lung, pancreatic, ovarian and breast, are in its R&D pipeline.

A urine-based liquid biopsy that reads whole biomolecular-signature patterns with machine learning rather than a single biomarker, avoiding blood draws and biopsies while remaining cheap enough to scale globally.

Funding

  • DebtFiled May 11, 2026Form D
    $1.6M/ $1.6M

Product

PanGIA Prostate Assay

Cancer diagnostic assay

An AI-integrated, urine-based liquid biopsy test for detecting clinically significant prostate cancer, replacing blood draws and invasive tissue biopsies with a simple urine sample.

  • Urine sample collection, no blood draw or tissue biopsy
  • Colorimetric biomolecular-signature profiling
  • Machine-learning-driven pattern recognition

Built for

Clinicians and health systems screening for cancer, plus payers and the patients they cover

People on file